Please assess the completion status of the following clinical trial:

Trial Title: To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.~* Healthy male or female infant between, and including, 6 and 14 weeks (42 - 104 days) of age at the time of first study vaccination in Portugal, France and Poland. A male or female infant between, and including, 6 and 12 weeks of age at the time of first study vaccination in Spain.~* Medically stable pre-term infants, born within a gestational period of 27 -36 weeks.~* Written informed consent obtained from the parent or guardian of the subject.~* Planned to be discharged from hospital's neonatal stay on or before the day of the first HRV vaccine/Placebo administration.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the HRV vaccine within 30 days preceding the first dose of HRV vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs since birth.~* Planned administration/ administration of a vaccines not foreseen by the study protocol from birth till study end.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* Any clinically significant history of chronic gastrointestinal disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness (subjects with severe broncho-pulmonary dysplasia requiring persistent oxygen-therapy will be excluded).~* History of any neurologic disorders or seizures. Grade I and II intra-ventricular bleeding are allowed.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins, and/or any blood products within one month (30 days) preceding the first dose of study vaccines or planned administration during the study period. Monoclonal anti-RSV therapy/prophylaxis and recombinant erythropoietin are allowed.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 14 Weeks
- Healthy Volunteers: t

Study Arms:
- Rotarix Group (Type: EXPERIMENTAL): All subjects received 2 oral doses of Rotarix vaccine, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
- Placebo Group (Type: PLACEBO_COMPARATOR): All subjects received 2 oral doses of placebo, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.

Based on this trial design, predict the completion outcome and termination type (if applicable).